Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
This article was originally published in Scrip
Amgen's RANK ligand inhibitor denosumab has been formally approved in Japan as Ranmark through local licensee Daiichi Sankyo for the indications of bone disorders stemming from bone metastases of solid tumours and bone complications of multiple myeloma.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.